{"company":{"id":3783084,"name":"STAR Therapeutics","domain":"star-therapeutics.com","url":"https://alion.io/company/world-3783084"},"section":"news","answer":"STAR Therapeutics: 19 headlines on record, 1 headline in the last 90 days. Its story counts 3 milestones.","figures":[{"label":"Headlines","value":"19"},{"label":"In 90 days","value":"1"},{"label":"Milestones","value":"3"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":14},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":3}],"news":[{"date":"2026-10-23","kind":"News","title":"Star Therapeutics Raises $200 Million To Advance Preclinical Pipeline Into The Clinic","source":"Pulse 2.0","url":"https://pulse2.com/star-therapeutics-raises-200-million-to-advance-preclinical-pipeline-into-the-clinic/"},{"date":"2026-07-06","kind":"Press release","title":"Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio","url":"https://investor.incyte.com/news-releases/news-release-details/incyte-completes-acquisition-vega-therapeutics-wholly-owned"},{"date":"2026-06-26","kind":"News","title":"Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/star-therapeutics-present-complete-data-130000292.html"},{"date":"2026-06-08","kind":"Blog","title":"Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders","url":"https://investor.incyte.com/news-releases/news-release-details/incyte-acquire-vega-therapeutics-wholly-owned-subsidiary-star"},{"date":"2026-06-08","kind":"News","title":"Star Tribune","source":"Star Tribune","url":"https://markets.financialcontent.com/startribune/article/bizwire-2026-6-8-incyte-to-acquire-vega-therapeutics-a-wholly-owned-subsidiary-of-star-therapeutics-expanding-its-hematology-portfolio-into-bleeding-disorders"},{"date":"2026-04-21","kind":"Blog","title":"Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis","url":"https://star-therapeutics.com/star-therapeutics-receives-fda-rare-pediatric-disease-and-breakthrough-therapy-designations-for-vga039-in-von-willebrand-disease-prophylaxis/"},{"date":"2026-01-05","kind":"Blog","title":"Star Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12","url":"https://star-therapeutics.com/star-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-on-monday-january-12/"},{"date":"2025-12-08","kind":"Blog","title":"Star Therapeutics details early data for blood disorder shot, weighs IPO potential","url":"https://endpoints.news/ash25-star-therapeutics-details-early-data-for-blood-disorder-shot-weighs-ipo/"},{"date":"2025-12-07","kind":"Blog","title":"ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success","url":"https://fiercebiotech.com/biotech/ash-star-antibody-sparkles-preview-potential-phase-3-bleeding-disease-success"},{"date":"2025-12-07","kind":"Blog","title":"Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting","url":"https://star-therapeutics.com/star-therapeutics-presents-interim-data-from-phase-12-multidose-study-of-vga039-in-von-willebrand-disease-demonstrating-substantial-bleed-reductions-in-all-patients-at-ash-annual-meeting/"},{"date":"2025-12-06","kind":"Blog","title":"ASH 2025: Von Willebrand disease is the most common bleeding disorder, though many people have never heard of it. Star Therapeutics is working on a solution that is already in phase 3","url":"https://biotechtv.com/post/star-therapeutics-ash-2025"},{"date":"2025-10-12","kind":"News","title":"Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders","source":"Pulse 2.0","url":"https://pulse2.com/star-therapeutics-125-million-series-d-raised-for-developing-antibodies-for-bleeding-disorders/"},{"date":"2025-09-30","kind":"News","title":"Star Therapeutics raises $125 million for breakthrough approach to inherited bleeding disorder","source":"bizjournals.com","url":"https://bizjournals.com/sanfrancisco/news/2025/09/30/von-willebrand-disease-vwd-star-therapeutics.html"},{"date":"2024-12-09","kind":"News","title":"Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024","source":"streetinsider.com","url":"https://streetinsider.com/Business+Wire/Star+Therapeutics+Presents+Interim+Clinical+Data+for+VGA039+in+Patients+with+Von+Willebrand+Disease+%28VWD%29+at+ASH+2024/24081350.html"}],"story":[{"title":"Raised a round Venture round $200M · Pulse 2.0","url":"https://pulse2.com/star-therapeutics-raises-200-million-to-advance-preclinical-pipeline-into-the-clinic/"},{"title":"Raised a round Series D $125M","url":"https://bizjournals.com/sanfrancisco/news/2025/09/30/von-willebrand-disease-vwd-star-therapeutics.html"},{"title":"Website went live first capture in the Wayback Machine","url":"https://web.archive.org/web/20180806233759/star-therapeutics.com"}],"as_of":"2026-11-18","cite":"STAR Therapeutics, News. Alion, Nov 18, 2026. https://alion.io/company/world-3783084/news","html_url":"https://alion.io/company/world-3783084/news","json_url":"https://alion.io/company/world-3783084/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-18T00:44:04Z"}}